NCT01585675

Brief Summary

The primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translation research, which will enable the investigators to detect lung cancer earlier, develop better therapies and explore screening and prevention strategies.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
111mo left

Started Nov 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress69%
Nov 2005Jul 2035

Study Start

First participant enrolled

November 3, 2005

Completed
6.5 years until next milestone

First Submitted

Initial submission to the registry

April 17, 2012

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 26, 2012

Completed
23.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2035

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2035

Last Updated

January 29, 2026

Status Verified

January 1, 2026

Enrollment Period

29.7 years

First QC Date

April 17, 2012

Last Update Submit

January 27, 2026

Conditions

Lung Neoplasms

Keywords

Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • Development of a comprehensive specimen banking program from patients with lung cancer for future translational research.

    No statistical analysis will be applied to the overall collection of samples. Rather, each project that utilized tissue bank resources will require an appropriate statistical plan to be submitted along with the initial tissue request.

    6 years

Study Arms (1)

Diagnosis/treatment of lung cancer

Specimen Banking

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.

You may qualify if:

  • Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.
  • Oral and written informed consent

You may not qualify if:

  • \. Any individual who does not give oral and written consent for participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado Cancer Center

Aurora, Colorado, 80045, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Tissue, blood, urine, and sputum, breath

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Adriaan VanBokhoven, PhD

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Brandi Kubala

CONTACT

303-724-1657brandi.kubala@cuanschutz.edu

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2012

First Posted

April 26, 2012

Study Start

November 3, 2005

Primary Completion (Estimated)

July 1, 2035

Study Completion (Estimated)

July 1, 2035

Last Updated

January 29, 2026

Record last verified: 2026-01

Locations

US(1)